Kanwaljit Chouhan, MD
Nephrology · Des Moines, IANPI 1033384086
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $277 of the $350 with a category attached, or 79.3%. 8 manufacturers reported payments, led by Amgen at 40.1% of the total.
Across 11 payments — averaging $31.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$140
- Mallinckrodt Enterprises LLC$91
- Daiichi Sankyo Inc.$26
- AstraZeneca$25
- Novartis$18
- Takeda Pharmaceuticals U.S.A., Inc.$17
- plus $32 from 2 others
What the payments were for
- Food & beverage$27779%
- Education$7321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 3 | $140 |
| Mallinckrodt Enterprises LLC | 2 | $91 |
| Daiichi Sankyo Inc. | 1 | $26 |
| AstraZeneca | 1 | $25 |
| Novartis | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Pfizer | 1 | $16 |
How this compares
$350 in reported general payments places this provider in the 60th percentile of 73 nephrology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JynarqueTolvaptan | 15 | $296,795 |
| Tacrolimus | 36 | $2,456 |
| Bumetanide | 88 | $2,167 |
| Febuxostat | 20 | $2,134 |
| Tamsulosin Hcl | 74 | $1,622 |
| Mycophenolic AcidMycophenolate Sodium | 16 | $1,555 |
| Mycophenolate Mofetil | 16 | $1,379 |
| Allopurinol | 188 | $1,093 |
| Doxazosin Mesylate | 67 | $1,028 |
| Metoprolol Succinate | 110 | $970 |
| Furosemide | 255 | $956 |
| Amlodipine Besylate | 197 | $920 |
| Lisinopril | 174 | $903 |
| Losartan Potassium | 165 | $819 |
| Carvedilol | 67 | $647 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Jynarque | $17 | $296,79515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 73 nephrology providers in Iowa.
Other nephrology in Des Moines
- Craig ShadurDes Moines$314K
- Prem ChandranDes Moines$19K
- Mark BelzDes Moines$2K
- Jobinson ThomasDes Moines$2K
- Arsalan AlviDes Moines$1K
- Robert SmithDes Moines$1K
- Sameer YaseenDes Moines$1K
- Jennifer ThompsonDes Moines$1K
- Dhivya SundaramurthyDes Moines$930
- Arani NanavatiDes Moines$930
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.